Astal Laboratories (ASTALLTD) Share Price Falls 9.88% Today; Price Action, Valuation and Sector View
- September 7, 2026
- Posted by: Harsh Piplani
- Category: News
Astal Laboratories Share Price fell to Rs 69.3 on 07 September 2026, down 9.88% for the day, taking the company’s market capitalisation to Rs 336.81 crore. The Micro Cap pharmaceutical stock opened at Rs 76.9, touched a high of Rs 77.4 and slipped to an intraday low of Rs 62.8, highlighting a sharp same-day re-pricing in today’s trade.
The supplied data confirms the price move but does not establish a company-specific reason behind it. What stands out instead is the contrast between weak one-day price action and a set of fundamentals that look relatively firm on the available numbers. The stock is trading at a P/E of 34.6 and a P/B of 1, while ROE is 32.12% and ROCE is 34.78%. That makes today’s decline notable not only because of the size of the move, but also because the stock’s valuation and profitability do not point to a simple, one-line interpretation.
Astal Laboratories (ASTALLTD) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 69.3 |
| Previous Close | Rs 76.9 |
| Today's Move | -Rs 7.60 (-9.88%) |
| Open | Rs 76.9 |
| High | Rs 77.4 |
| Low | Rs 62.8 |
| Turnover | Rs 0.11 crore |
| Market Capitalisation | Rs 336.81 crore |
| Market Cap Category | Micro Cap |
Astal Laboratories Share Price Today showed a sharp downward session. The stock moved from the previous close of Rs 76.9 to Rs 69.3, a decline of Rs 7.6 or 9.88%. It opened flat at Rs 76.9, briefly touched Rs 77.4, then fell to Rs 62.8 before recovering some ground into the latest quoted level.
The intraday range of Rs 14.6 was wide relative to the stock price, which signals elevated volatility through the session. Turnover was Rs 0.11 crore. For a Micro Cap name, that combination of a broad range and a steep close-to-close decline is usually enough to draw market attention even when the available dataset does not attach a specific trigger.
Technical markers add more context. The RSI stands at 46.87, which places momentum in a neutral-to-soft zone rather than at an extreme. The stock is also below its 50-day moving average of Rs 81.93 and its 200-day moving average of Rs 78.59. That indicates the current price is sitting under both medium-term and longer-term reference levels based on the supplied data.
Astal Laboratories (ASTALLTD) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 336.81 crore |
| P/E Ratio | 34.6x |
| P/B Ratio | 1x |
| ROE | 32.12% |
| ROCE | 34.78% |
| EPS | Rs 2.22 |
| Book Value Per Share | Rs 76.99 |
| Dividend Yield | 0% |
On fundamentals, the picture is mixed but interesting. Astal Laboratories is a Micro Cap company with a market value of Rs 336.81 crore. The stock trades at 34.6 times earnings and 1 time book value. A P/E at this level is not especially low, but the P/B ratio suggests the market is valuing the company close to its stated net worth.
Profitability metrics are stronger than the balance-sheet multiple alone might imply. ROE stands at 32.12% and ROCE at 34.78%, both high in absolute terms on the supplied numbers. EPS is Rs 2.22, while book value per share is Rs 76.99, above the current price of Rs 69.3. Dividend yield is listed at 0%, so there is no dividend support reflected in this dataset.
That leaves investors with a stock where one-day price weakness sits beside high return ratios and a low P/B reading. It does not automatically make the stock cheap or expensive; instead, it points to the need for wider industry comparison before drawing conclusions from the headline decline alone.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 34.6x |
| Benchmark Median P/E | 32.83x |
| Benchmark Average P/E | 48.79x |
| Benchmark P/E Range | 3.2x to 659.73x |
| Company P/B Ratio | 1x |
| Benchmark Median P/B | 2.92x |
| Benchmark Average P/B | 4.34x |
| Company ROE | 32.12% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 10.63% |
| Company ROCE | 34.78% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.19% |
| Company Market Capitalisation | Rs 336.81 crore |
| Benchmark Median Market Cap | Rs 674.09 crore |
| Benchmark Average Market Cap | Rs 13,840.86 crore |
Astal Laboratories operates in Healthcare, specifically Pharmaceuticals & Drugs. In the same-industry benchmark of 204 companies, its P/E of 34.6 is slightly above the median of 32.83 and below the average of 48.79. That places the stock near the middle of the industry valuation distribution, not at an extreme.
The P/B comparison is different. At 1, the company’s price-to-book ratio is below the industry median of 2.92 and average of 4.34. Profitability is stronger than benchmark norms: ROE of 32.12% is above the median of 11.78% and average of 10.63, while ROCE of 34.78% is above the median of 13.65% and average of 13.19.
Size, however, remains small relative to the group. Astal Laboratories’ market capitalisation of Rs 336.81 crore is below the benchmark median of Rs 674.09 crore and far below the benchmark average of Rs 13,840.86 crore. So the sector view is of a much smaller company with above-benchmark return ratios, a below-benchmark P/B, and a P/E that is only modestly above the median.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,55,633.71 | 37.67 | 5.27 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,41,576.41 | 82.59 | 13.68 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,84,478.41 | 84.58 | 20.55 | 26.76 | 19.27 |
| Cipla | CIPLA | 1,11,888.39 | 33.19 | 3.18 | 11.83 | 16 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,820.18 | 24.78 | 4.15 | 19.69 | 21.39 |
Compared with larger listed pharma companies, Astal Laboratories is much smaller by market value. Its Rs 336.81 crore market cap is far below Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Cipla and Zydus Lifesciences, each of which is above Rs 1,11,000 crore in the supplied peer set.
On valuation, the company’s P/E of 34.6 is below Sun Pharma’s 37.67, far below Divi’s 82.59 and Torrent’s 84.58, slightly above Cipla’s 33.19, and above Zydus Lifesciences’ 24.78. The P/B ratio of 1 is lower than all five peers, whose P/B values range from 3.18 to 20.55.
Return ratios are the most notable area of contrast. ROE of 32.12% is above all five named peers, and ROCE of 34.78% is also above each of them on the provided figures. That does not explain today’s decline, but it does show why the stock may remain under watch despite the day’s weakness.
Why Investors Are Watching Astal Laboratories
- The stock fell 9.88% in a single session to Rs 69.3.
- The intraday swing was sharp, with a high of Rs 77.4 and a low of Rs 62.8.
- RSI is 46.87, while the price is below both the 50 DMA of Rs 81.93 and the 200 DMA of Rs 78.59.
- P/B of 1 is below industry median levels, while P/E of 34.6 is only slightly above the industry median.
- ROE and ROCE are well above industry median and average values in the supplied benchmark set.
About Astal Laboratories
Astal Laboratories is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied data, it is being assessed against a wide set of same-industry companies on valuation, profitability and size. That context matters because today’s move is happening in a smaller listed pharma name whose return ratios compare strongly on the available figures.
Track Astal Laboratories Share Price on Univest
UseAstal Laboratories (ASTALLTD) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors can track Astal Laboratories Share Price on Univest for live price moves, valuation ratios, technical levels, peer comparison and broader market context. That helps place the current decline in a framework built on actual market data rather than speculation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Astal Laboratories Share Price falling today?
Ans. The supplied data confirms that the stock fell 9.88% to Rs 69.3 today. However, the dataset does not establish any company-specific catalyst, so the verified takeaway is the price event itself and the wide intraday range.
What is Astal Laboratories Share Price Today?
Ans. Astal Laboratories Share Price Today is Rs 69.3. The stock was down Rs 7.6 from the previous close of Rs 76.9, representing a single-day decline of 9.88% as of the supplied market update.
What does today’s price action show for Astal Laboratories?
Ans. Today’s price action shows a flat open at Rs 76.9, a high of Rs 77.4 and a low of Rs 62.8 before the stock settled at Rs 69.3. That points to a volatile session with clear downward pressure and some.
Is Astal Laboratories expensive based on P/E and P/B?
Ans. The stock trades at a P/E of 34.6 and a P/B of 1. Its P/E is slightly above the industry median of 32.83, while its P/B is below the industry median of 2.92, giving a mixed valuation picture on the.
How profitable is Astal Laboratories on the supplied data?
Ans. The company shows ROE of 32.12% and ROCE of 34.78%, both above the Pharmaceuticals & Drugs industry medians of 11.78% and 13.65. On the available numbers, profitability metrics are notably stronger than benchmark norms.
What is the book value and EPS of Astal Laboratories?
Ans. Astal Laboratories has an EPS of Rs 2.22 and a book value per share of Rs 76.99. With the current price at Rs 69.3, the stock is trading below its stated book value in the supplied dataset.
How does Astal Laboratories compare with pharma peers?
Ans. Astal Laboratories is far smaller by market cap than peers such as Sun Pharma, Divi’s, Torrent, Cipla and Zydus. However, its ROE of 32.12% and ROCE of 34.78% are higher than each of those supplied peers.
What sector does Astal Laboratories belong to?
Ans. Astal Laboratories belongs to the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. The benchmark comparison in the supplied data covers 204 same-industry companies. The stock belongs to the Healthcare sector.
What should investors monitor next?
Ans. Investors may watch whether the stock stabilises after today’s 9.88% decline, how it trades relative to the 50 DMA of Rs 81.93 and the 200 DMA of Rs 78.59, and whether valuation continues to look different from sector averages on.
